


## Meta-analysis of genome-wide association data identifies two loci influencing age at menarche

John R B Perry<sup>1,2,3</sup>, Lisette Stolk<sup>2-4,23</sup>, Nora Franceschini<sup>5,23</sup>, Kathryn L Lunetta<sup>6,7,23</sup>, Guangju Zhai<sup>8,23</sup>, Patrick F McArdle<sup>9,23</sup>, Albert V Smith<sup>10,23</sup>, Thor Aspelund<sup>10,11</sup>, Stefania Bandinelli<sup>12</sup>, Eric Boerwinkle<sup>13</sup>, Lynn Cherkas<sup>8</sup>, Gudny Eiriksdottir<sup>10</sup>, Karol Estrada<sup>2</sup>, Luigi Ferrucci<sup>14</sup>, Aaron R Folsom<sup>15</sup>, Melissa Garcia<sup>16</sup>, Vilmundur Gudnason<sup>10,11</sup>, Albert Hofman<sup>3,4</sup>, David Karasik<sup>6,17</sup>, Douglas P Kiel<sup>6,17</sup>, Lenore J Launer<sup>16</sup>, Joyce van Meurs<sup>2,4</sup>, Michael A Nalls<sup>18</sup>, Fernando Rivadeneira<sup>2-4</sup>, Alan R Shuldiner<sup>9</sup>, Andrew Singleton<sup>18</sup>, Nicole Soranzo<sup>8,19</sup>, Toshiko Tanaka<sup>20</sup>, Jenny A Visser<sup>2</sup>, Michael N Weedon<sup>1</sup>, Scott G Wilson<sup>8,21</sup>, Vivian Zhuang<sup>7</sup>, Elizabeth A Streeten<sup>9,23</sup>, Tamara B Harris<sup>16,23</sup>, Anna Murray<sup>1,23</sup>, Tim D Spector<sup>8,23</sup>, Ellen W Demerath<sup>15,23</sup>, André G Uitterlinden<sup>2-4,23</sup> & Joanne M Murabito<sup>6,22,23</sup>

We conducted a meta-analysis of genome-wide association data to detect genes influencing age at menarche in 17,510 women. The strongest signal was at 9q31.2 ( $P = 1.7 \times 10^{-9}$ ), where the nearest genes include *TMEM38B*, *FKTN*, *FSD1L*, *TAL2* and *ZNF462*. The next best signal was near the *LIN28B* gene (rs7759938;  $P = 7.0 \times 10^{-9}$ ), which also influences adult height. We provide the first evidence for common genetic variants influencing female sexual maturation.

Menarche is the start of menstruation and occurs at a mean age of approximately 13 years, normally about 2 years after the onset of puberty<sup>1</sup>. Twin and family studies suggest a significant genetic component to menarcheal age, with at least 50% heritability<sup>2-4</sup>. Linkage and candidate gene studies have not confirmed any loci that influence normal variation in age at menarche<sup>4,5</sup>. Genome-wide association (GWA) studies have been successful in identifying many variants associated with complex disease and quantitative traits and we



**Figure 1** Genomic context (based on NCBI B36) of the top two independent signals at 9q31.2 and 6q21 plotted against association  $-\log_{10} P$  values. Only UCSC Refseq genes are shown.  $r^2$  between each SNP and the top signal is color coded:  $>0.8$ , red;  $0.5-0.8$ , orange;  $0.2-0.5$ , yellow;  $<0.2$ , unfilled. Blue represents SNP with lowest  $P$  value. Chromosome positions are based on build hg18.

<sup>1</sup>Institute of Biomedical and Clinical Science, Peninsula Medical School, Exeter, UK. <sup>2</sup>Department of Internal Medicine. <sup>3</sup>Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands. <sup>4</sup>Netherlands Genomics Initiative-sponsored Netherlands Consortium for Healthy Aging (NGI-NCHA). <sup>5</sup>Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA. <sup>6</sup>The National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA. <sup>7</sup>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA. <sup>8</sup>Department of Twin Research & Genetic Epidemiology, King's College London, London, UK. <sup>9</sup>Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA. <sup>10</sup>Icelandic Heart Association, Kopavogur, Iceland. <sup>11</sup>University of Iceland, Reykjavik, Iceland. <sup>12</sup>Geriatric Unit, Azienda Sanitaria di Firenze, Florence, Italy. <sup>13</sup>Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas, USA. <sup>14</sup>Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland, USA. <sup>15</sup>Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA. <sup>16</sup>Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA. <sup>17</sup>Hebrew SeniorLife Institute for Aging Research and Harvard Medical School, Boston, Massachusetts, USA. <sup>18</sup>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA. <sup>19</sup>Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK. <sup>20</sup>Medstar Research Institute, National Institute on Aging, Baltimore, Maryland, USA. <sup>21</sup>School of Medicine & Pharmacology, University of Western Australia and Department of Endocrinology & Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. <sup>22</sup>Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA. <sup>23</sup>These authors contributed equally to this work. Correspondence should be addressed to A.G.U. (a.g.uitterlinden@erasmusmc.nl).

Received 12 February; accepted 21 April; published online 17 May 2009; doi:10.1038/ng.386

**Table 1 Genome-wide significant associations with age at menarche**

SNP	Study	N	Allele	Frequency	Imputation quality	Effect (years)	s.e.	P value
rs2090409	ARIC	4,247	A	0.31	1.00	-0.10	0.04	0.004
	FHS	3,801	A	0.31	0.99	-0.07	0.04	0.07
	RSI	3,175	A	0.34	1.01	-0.08	0.04	0.06
	TwinsUK	2,276	A	0.32	0.99	-0.11	0.03	0.0003
	AGES-Reykjavik	1,849	A	0.27	0.99	-0.08	0.05	0.09
	RSII	1,000	A	0.35	1.06	-0.15	0.07	0.04
	InCHIANTI	597	A	0.33	0.98	-0.26	0.09	0.005
	HAPI Heart Study	565	A	0.28	0.95	0.03	0.10	0.7809
<b>Meta-analysis</b>	17,510	A	0.31	1.00	-0.10	0.02	$1.7 \times 10^{-9}$	
rs7759938	ARIC	4,247	C	0.33	0.94	0.12	0.04	0.001
	FHS	3,801	C	0.33	0.90	0.10	0.04	0.009
	RSI	3,175	C	0.31	1.00	0.06	0.04	0.16
	TwinsUK	2,276	C	0.32	0.98	0.06	0.03	0.04
	AGES-Reykjavik	1,849	C	0.34	1.00	0.08	0.04	0.07
	RSII	1,000	C	0.30	0.94	0.09	0.08	0.27
	InCHIANTI	597	C	0.29	0.98	0.24	0.09	0.008
	HAPI Heart Study	565	C	0.23	0.91	0.34	0.11	0.002
<b>Meta-analysis</b>	17,510	C	0.33	0.96	0.09	0.02	$7.0 \times 10^{-9}$	

Meta-analysis *P* values are corrected by individual-study genomic control inflation factors. Alleles are based on forward strand and positions on NCBI build 36. Meta-analysis frequency is calculated as weighted average across all studies. Imputation quality refers to the imputation quality score generated by MACH (oevar) / SNPTEST (proper\_info).

therefore used this approach to identify genes involved in determining age at menarche. As earlier age at menarche is associated with shorter stature and obesity, the identified variants may not only clarify the genetic control of female sexual maturation but may also point to regulatory mechanisms involved in normal human growth and obesity.

We carried out a meta-analysis of 17,510 females from eight different population-based cohorts: Age/Gene Environment Susceptibility-Reykjavik Study (AGES-Reykjavik), Atherosclerosis Risk in Communities (ARIC) Study, Framingham Heart Study (FHS), Amish HAPI Heart Study, InCHIANTI Study, Rotterdam Study I and II and TWINS UK Study (**Supplementary Note** online). Women of European descent, with self-reported age at menarche between 9 and 17 years (representing the 1st to 99th percentile, with mean age at menarche of 13.12 (s.d. 1.5) years), were included. Agreement between adult-recalled and prospectively collected age at menarche is reported to be good ( $\kappa$  statistic = 0.81)<sup>6</sup>. Each study conducted a GWA analysis using linear regression or linear mixed-effects models with an additive genetic model adjusting for birth year or birth cohort (FHS), with additional adjustments for population structure when appropriate. Approximately 2.55 million autosomal SNPs, imputed with reference to the HapMap CEU panel, passed quality control criteria. We then conducted a meta-analysis using a fixed-effects model based on inverse variance weighting. Full details of cohorts and methods are given in **Supplementary Table 1** and **Supplementary Methods** online.

Twenty-eight SNPs passed the conventional genome-wide significance threshold of  $P < 5 \times 10^{-8}$  and were at either 9q31.2 or 6q21 (**Supplementary Table 2** and **Supplementary Fig. 1** online). The 18 SNPs on chromosome 9 were in linkage disequilibrium (LD), with  $r^2 > 0.31$ , as were the 10 SNPs on chromosome 6, with  $r^2 > 0.96$  (**Fig. 1** and **Supplementary Table 2**). To identify more than one signal that could account for the association findings, we carried out conditional analysis adjusting for the SNP with the lowest *P* value in the region (rs7759938 for chromosome 6 and rs2090409 for chromosome 9). Within 1 Mb flanking each SNP, the lowest adjusted *P* values for association with age

at menarche were  $P = 0.0017$  and  $P = 0.0077$  for chromosomes 9 (1,030 SNPs) and 6 (775 SNPs), respectively. These findings suggest a single signal accounting for the associations at each locus. The quantile-quantile plot (**Supplementary Fig. 2** online) showed modest deviation away from the null when these top two signals were removed, suggesting the presence of additional loci for this trait.

The strongest signal at 9q31.2 was observed with rs2090409, where each A allele was associated with approximately a 5-week reduction in menarcheal age ( $P = 1.7 \times 10^{-9}$ ). All studies showed consistent evidence of association with the same direction of effect in all but one study, similar effect sizes and *P* values between 0.8 and 0.0003 (**Table 1**). The recombination region containing rs2090409 includes only a hypothetical gene (*BC039487*). Outside of this, the only RefSeq gene within a 1-Mb window is a transmembrane protein gene, *TMEM38B*, which is approximately 400 kb proximal to the GWAS signal. In mice, *TMEM38B* is expressed strongly in brain and the null mutation is neonatal lethal. Within 2 Mb of the signal, genes include *SLC44A1*, *FKTN*, *FSD1L*, *TAL2* and *ZNF462*, none of which is an obvious candidate gene for involvement in menarche. However, a SNP in *ZNF462*, 650 kb from our signal but not in LD ( $r^2 = 0.086$ ), has been previously associated with variation in height<sup>6</sup>.

The 6q21 signal was within a recombination interval that included only one gene, *LIN28B* (**Fig. 1**) and was also associated with approximately a 5-week reduction in menarcheal age per T allele (rs7759938;  $P = 7.0 \times 10^{-9}$ ). The effect was consistent across all studies, with *P* values between 0.27 and 0.001 (**Table 1**). A common variant in the *LIN28B* gene has previously been associated with normal variation in adult height<sup>7</sup>. The most significant menarche-associated variant (rs7759938) and the previously reported height variant (rs314277) lie within 28.7 kb of each other and are likely to represent the same signal, as  $r^2 = 0.26$  and  $D' = 1$  in HapMap. The allele associated with earlier age at menarche is associated with decreased height, which is consistent with epidemiological data. Early menarche has been correlated with reduced stature, and the mechanism is probably mediated through earlier exposure to estrogens resulting in earlier closure of the epiphyseal plates<sup>8</sup>. We therefore tested all

published common variants influencing height—44 independent loci—for association with age at menarche in our dataset<sup>9</sup>. Six of the alleles were also associated with menarcheal age ( $P < 0.05$ ), with the strongest associations at *LIN28B* ( $P = 0.0001$ ) and *PXMP3* ( $P = 0.003$ ) (Supplementary Table 3 online). We also tested the association of the newly identified menarche-associated variant, rs7759938, with measured height in our study population (Supplementary Methods) and found that it was associated with height,  $P_{\text{meta}} = 0.0001$ , in the same direction in all but one study; that is, the C allele was associated with reduction in age at menarche and also reduced stature. The published height SNP (rs314277) did not reach nominal significance with height in our study ( $P_{\text{meta}} = 0.26$ ). These data suggest that some of the previously identified loci that influence adult height may also have a general role in adolescent growth.

At a given chronologic age, girls with earlier age at menarche tend to have greater body mass index (BMI) and adiposity than girls with a later age at menarche<sup>10–12</sup>. A marked secular decline in age at menarche occurred in Europe in the nineteenth and early twentieth centuries, which has been attributed to improved nutrition and health<sup>1</sup>. This trend may be continuing as a consequence of the obesity epidemic<sup>13</sup> and may involve a common metabolic response to the current nutritional environment<sup>14</sup> or be attributable, at least in part, to shared genetic influences or pleiotropy<sup>15</sup>. We therefore investigated the effect on menarcheal age of the ten currently known common gene variants associated with variation in BMI. Of these ten loci, eight showed an association in the direction consistent with epidemiological data ( $P = 1.6 \times 10^{-6}$ , based on Fisher's combined probability test:  $-2 \times \sum(\ln P)$  against  $\chi^2$  on  $(10 \times 2)$  df), and five were nominally significant ( $P < 0.05$ ) (Supplementary Table 4 online). The two loci with the largest observed effects on BMI (*FTO* and *TMEM18*) also had the strongest evidence for association with menarcheal age ( $P = 0.0008$  and  $7.0 \times 10^{-5}$ , respectively).

This study provides the first evidence for common genetic variants influencing normal variation in the timing of female sexual maturation. Our findings also indicate a genetic basis for the phenotypic associations between age at menarche and both height and BMI.

Note: Supplementary information is available on the Nature Genetics website.

#### ACKNOWLEDGMENTS

We are indebted to the participants and staff of the studies for their important contributions. Full individual study acknowledgements are listed in the Supplementary Methods.

#### AUTHOR CONTRIBUTIONS

Statistical analyses: J.R.B.P., L.S., N.F., K.L.L., G.Z., P.F.M., A.V.S., T.A., K.E., V.G., F.R., N.S., T.T., M.N.W. and V.Z. Sample collection, preparation: N.F., A.V.S., T.A., S.B., E.B., L.C., G.E., L.F., A.R.F., V.G., A.H., S.G.W., T.B.H., T.D.S., E.W.D. and A.G.U. Genotyping: E.B., F.R., A.S., N.S. and A.G.U. Manuscript writing: J.R.B.P., L.S., P.F.M., A.V.S., T.A., G.E., V.G., E.A.S., A.M., E.W.D. and A.G.U. Review and revision of the manuscript: J.R.B.P., L.S., N.F., K.L.L., G.Z., P.F.M., A.V.S., T.A., S.B., E.B., L.C., G.E., K.E., L.F., A.R.F., M.G., V.G., A.H., D.K., D.P.K., L.J.L., J.v.M., M.A.N., F.R., A.R.S., A.S., N.S., T.T., J.A.V., M.N.W., S.G.W., V.Z., E.A.S., T.B.H., A.M., T.D.S., E.W.D., A.G.U. and J.M.M. Intellectual input: J.R.B.P., L.S., N.F., K.L.L., P.F.M., E.B., G.E., A.R.F., V.G., D.K., D.P.K., J.A.V., S.G.W., A.M., A.G.U. and J.M.M. Study design: J.R.B.P., L.S., K.L.L., G.Z., A.V.S., T.A., S.B., G.E., L.F., V.G., A.H., D.K., D.P.K., A.M., T.D.S., A.G.U. and J.M.M.

Published online at <http://www.nature.com/naturegenetics/>

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>

1. Marshall, W.A. & Tanner, J.M. *Arch. Dis. Child.* **44**, 291–303 (1969).
2. Towne, B. *et al. Am. J. Phys. Anthropol.* **128**, 210–219 (2005).
3. Snieder, H., MacGregor, A.J. & Spector, T.D. *J. Clin. Endocrinol. Metab.* **83**, 1875–1880 (1998).
4. Anderson, C.A. *et al. J. Clin. Endocrinol. Metab.* **93**, 3965–3970 (2008).
5. Gajdos, Z.K.Z. *et al. J. Clin. Endocrinol. Metab.* **93**, 4290–4298 (2008).
6. Bosetti, C., Tavani, A., Negri, E., Trichopoulos, D. & La Vecchia, C. *J. Clin. Epidemiol.* **54**, 902–906 (2001).
7. Lettre, G. *et al. Nat. Genet.* **40**, 584–591 (2008).
8. Onland-Moret, N.C. *et al. Am. J. Epidemiol.* **162**, 623–632 (2005).
9. Weedon, M.N. & Frayling, T.M. *Trends Genet.* **24**, 595–603 (2008).
10. Anderson, S.E., Dallal, G.E. & Must, A. *Pediatrics* **111**, 844–850 (2003).
11. Garn, S., LaVelle, M., Rosenberg, K. & Hawthorne, V. *Am. J. Clin. Nutr.* **43**, 879–883 (1986).
12. van Lenthe, F., Kemper, C. & van Mechelen, W. *Am. J. Clin. Nutr.* **64**, 18–24 (1996).
13. Euling, S.Y. *et al. Pediatrics* **121**, S172–S191 (2008).
14. Harris, M.A., Prior, J.C. & Koehoorn, M. *J. Adolesc. Health* **43**, 548–554 (2008).
15. Wang, W., Zhao, L.-J., Liu, Y.-Z., Recker, R.R. & Deng, H.-W. *Int. J. Obes. (Lond.)* **30**, 1595–1600 (2006).